Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30804857 | 1.00 | ALDH1A1 (0.45) | ALDH1A1PPARADNMT3ALMNANLRP3 | |
| SCHEMBL24627785 | 1.00 | ALDH1A1 (0.45) | ALDH1A1PPARADNMT3ALMNANLRP3 | |
| SCHEMBL27174799 | 0.97 | ALDH1A1 (0.44) | ALDH1A1PPARADNMT3ALMNANLRP3 | |
| SCHEMBL24627887 | 0.97 | ALDH1A1 (0.44) | ALDH1A1PPARADNMT3ALMNANLRP3 | |
| SCHEMBL27174780 | 0.96 | ALDH1A1 (0.43) | ALDH1A1PPARADNMT3ALMNANLRP3 | |
| SCHEMBL24627888 | 0.96 | ALDH1A1 (0.43) | ALDH1A1PPARADNMT3ALMNANLRP3 | |
| SCHEMBL24627900 | 0.92 | PSMB5 (0.44) | ALDH1A1DNMT3ALMNAPSMB5MMP2 | |
| SCHEMBL27174817 | 0.92 | PSMB5 (0.44) | ALDH1A1DNMT3ALMNAPSMB5MMP2 | |
| SCHEMBL24627788 | 0.91 | RAB9A (0.46) | ALDH1A1LMNA | |
| SCHEMBL27174793 | 0.91 | RAB9A (0.46) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092737-A1 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092737-A1 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | SYMPK, SLC10A2, SLC10A1 | ALDH1A1 274/4885PPARA 657/4885DNMT3A 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.